培米替尼在哪可以买得到

(pemigatinib) is a selective FGFR tyrosine kinase inhibitor jointly developed by Innovent Biologics and Incyte. It was approved by the U.S. Food and Drug Administration (FDA) under the accelerated approval process on April 17, 2020, for the treatment of locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement.

The drug is marketed as tablets, available in three specifications. Each tablet contains 4.5 mg, 9 mg, and 13.5 mg of active ingredients. The additives or excipients include magnesium stearate, microcrystalline cellulose, and sodium carboxymethyl starch. The recommended dose of pemetinib is 13.5 mg qd. The drug should be taken continuously for 02 weeks and then discontinued for 1 week. A course of treatment is 3 weeks. Treatment should be continued until disease progression or intolerable toxicity occurs.

Pemetinib selectively inhibits the growth of tumor cells by inhibiting FGFR1-3 phosphorylation and signaling processes, blocking the constitutive activation of FGFR signaling caused by FGFR amplification and fusion. Preclinical studies have shown that pemetinib shows good anti-tumor activity against FGFR1~3 mutated tumor cells in cell line models and mouse human tumor xenograft models.

: Diarrhea, nausea, change in taste, vomiting, loss of appetite, weight loss, constipation, stomach pain, mouth sores, dry mouth and/or dry skin; decreased urine output; or rapid heartbeat.

Where can I buy pemetinib? Pemetinib is not yet available on the market in China, so patients who are looking for medicine have always had no way to find medicine in China, but they are in desperate need of treatment with this drug. At this time, more patients chose other versions of pemetinib for treatment. How to purchase other versions of pemetinib has become a problem. At this time, it is recommended that patients contact the domestic and overseas medical service organization Medical Companion Travel to help you purchase the drug. For specific prices and information about pemetinib, please contact Medical Companion Travel for your answer.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.